Since triple-negative breast cancer (TNBC) lacks an effective treatment target, that is, classic estrogen receptor (ERα), progesterone receptor (PgR), or human epidermal growth factor receptor-2 (HER2), chemotherapy is the most established pharmacotherapy for patients with TNBC. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.